20149 WEBCAST: Changing the Paradigm of CMV Management: New Science and More Choices for Challenging Cases in the HCT Setting

Cytomegalovirus (CMV) is a leading opportunistic infection in immunocompromised patients, including allogeneic hematopoietic stem cell transplant (HCT) recipients, where primary infection or reactivation is associated with increased morbidity and mortality. Antiviral drugs are the mainstay for the prevention of CMV infection and disease, most commonly with valganciclovir. However, valganciclovir use is often associated with adverse drug reactions, most notably leukopenia and neutropenia, and its widespread use has led to the emergence of antiviral resistance. Foscarnet and cidofovir, however, are associated with nephrotoxicity. After many years of few tangible advances, we are now experiencing an exciting period characterized by novel antiviral agents for CMV. Indeed, letermovir was recently approved for CMV prophylaxis in allogeneic HCT recipients, and data suggest that maribavir has the potential to address the unmet need of treating relapsed or resistant CMV infections. In this activity, based on a live symposium, experts offer insight into managing CMV in HCT recipients in a new era of antiviral therapy. Foundational guidance is combined with a discussion of real cases. Hear about best practices in preventing CMV infection in patients undergoing HCT, as well as the potential role of novel antiviral therapies in resistant/refractory CMV.

This activity can be accessed using the following URL: www.peerview.com/ZXF

Target Audience

This activity has been designed to meet the educational needs of hematologistoncologists, oncologists, BMT specialists, BMT nurse specialists, and other clinicians involved in the management of transplant recipients at risk for CMV.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Discuss the burden of cytomegalovirus (CMV) infection among hematopoietic stem cell transplant (HCT) recipients
  • Assess the latest clinical trial data regarding novel strategies to prevent and treat CMV infection in the HCT setting
  • Employ strategies to prevent and treat CMV infection in individual HCT recipients, considering current evidence, expert recommendations, and clinical trial enrollment for appropriate patients
Additional information

CME Coordinator Contact Information

Name: 
Megan Cowell
Phone Number: 
+1 (405) 735-7206
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.
Course opens: 
03/20/2020
Course expires: 
03/19/2021
Cost:
$0.00

Support Statement
This educational activity is supported by independent medical educational grants from Merck & Co., Inc. and Shire.

In accordance with ACCME requirements, The Medical College of Wisconsin has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Chair & Presenter

Roy F. Chemaly, MD, MPH, FIDSA, FACP Professor of Medicine Director, Infection Control Section Director, Clinical Virology Research Department of Infectious Disease, Infection Control and Employee Health The University of Texas MD Anderson Cancer Center Houston, Texas

Roy F. Chemaly, MD, MPH, FIDSA, FACP, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for Ansun BioPharma; Chimerix; Clinigen Group plc.; Janssen Pharmaceuticals, Inc.; Kyorin Pharmaceutical Co., Ltd; Merck & Co., Inc.; Oxford Immunotec USA, Inc.; Paratek Pharmaceuticals, Inc.; Pulmotect, Inc.; ReViral Ltd; Shire; and Xenex Laboratories. Grant/Research Support from Ansun BioPharma; Chimerix; Eurofins Viracor, Inc.; Gilead; Merck & Co., Inc.; Karius, Inc.; Oxford Immunotec USA, Inc.; Pulmotect, Inc.; and Xenex Laboratories.

Co-Chair and Presenter Genovefa Papanicolaou, MD, FIDSA Director, Clinical Trials, Infectious Disease Specialist Memorial Sloan Kettering Cancer Center Professor, Weill Cornell Medical College Cornell University New York, New York

Genovefa Papanicolaou, MD, FIDSA, has a financial interest/relationship or affiliation in the form of: Consultant and/or Advisor for ADMA Biologics, Inc.; Astellas Pharma US, Inc.; Merck & Co., Inc.; Nabriva Therapeutics plc; Octapharma; Shionogi Inc.; and Siemens. Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; and Merck & Co., Inc. Speakers Bureau participant with Amplyx and Merck & Co., Inc. Data Safety Monitoring Board for Amplyx and Merck & Co., Inc.

Medical Director Kathryn B. Charalambous, PhD PVI, PeerView Institute for Medical Education Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity

The Medical College of Wisconsin (MCW) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by MCW for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. Providership, Credit, and Support This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians. The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Hours of Participation for Allied Health Care Profession,

Disclosure of Unlabeled Use The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use. No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling. The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

 

 

image image
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Care Professionals:

The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.

Providership

This CME activity is jointly provided by The Medical College of Wisconsin and PVI, PeerView Institute for Medical Education.

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
    AMA PRA Category 1 Credit(s)™
  • 1.00 Hours of Participation
    Hours of Participation credit.

Price

Cost:
$0.00
Please login or register to take this course.